Key Stats for Eli Lilly Stock
- Current Price: $1,065.00
- Street Target (Mean): ~$1,211
- TIKR Mid-Case Target: ~$2,029
- Potential Total Return (Mid): ~91%
- Annualized IRR: ~15% / year
- Q1 2026 Earnings Reaction: +3.07% (4/30/26)
- Max Drawdown: 23.64% (8/8/25)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Eli Lilly and Company (LLY) just produced obesity trial data that no drug developer has ever produced before, and the stock went up about 1%.
On May 21, Lilly announced that retatrutide, its investigational triple hormone receptor agonist (a drug targeting three separate metabolic hormones simultaneously), delivered average weight loss of 28.3% over 80 weeks in the Phase 3 TRIUMPH-1 trial. Nearly half of the participants on the highest dose lost at least 30% of their body weight, a threshold Lilly cited as historically associated with bariatric surgery, per a 2014 NIH symposium published in JAMA Surgery. These are topline results that have not yet been peer-reviewed.
For context: semaglutide achieved 14.9% weight loss in the STEP 1 trial. Tirzepatide, the molecule in Lilly’s own Zepbound, reached up to 22.5% in SURMOUNT-1. Retatrutide’s 28.3% sits in a different category entirely.
The data was historic. The market reaction was muted. That gap is what investors need to think through.
What the Market Had Already Priced In
Investors had expected strong TRIUMPH-1 results for months. The Q1 earnings call on April 30 had flagged this trial explicitly as the next major catalyst, and the stock had already recovered sharply from its year-to-date lows after a large earnings beat.
What the market may not have fully modeled is how deliberately management had mapped retatrutide’s commercial role before the results arrived. On the Q1 call, Ken Custer, President of Lilly Cardiometabolic Health, described a portfolio built around patient choice: Zepbound for injectable GLP-1 users, Foundayo (orforglipron) for patients who prefer a daily pill with no food restrictions, retatrutide for patients seeking the highest weight reduction, and eloralintide (a selective amylin receptor agonist in Phase 3) for patients who need a non-GLP-1 mechanism or want an add-on therapy. Four mechanisms, four patient populations, one manufacturing platform.
This is not a backup drug. It is the capstone of a deliberate portfolio architecture that management described before the efficacy data was even public.
See historical and forward estimates for Eli Lilly stock (It’s free!) >>>
The Trial Data and What Comes Next
TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes. All three tested doses met the primary and key secondary endpoints at 80 weeks. At 12 mg, participants lost an average of 70.3 pounds, with 45.3% achieving at least 30% body weight loss. An extension for participants with a BMI of 35 or higher showed an average loss of 85 pounds (30.3%) at 104 weeks. Even the lowest 4 mg dose, requiring only a single escalation step, produced 19% average weight loss with a discontinuation rate below placebo.
TRIUMPH-1 is the first of four registrational trials. TRIUMPH-2 studies retatrutide in type 2 diabetes and obesity. TRIUMPH-3, likely the most commercially significant, evaluates the drug in patients with established cardiovascular disease, the segment that unlocks the highest-volume payer coverage. Additional subgroup readouts for knee osteoarthritis and sleep apnea will follow separately.
The cardiovascular data is the pivot point. For comparison, Lilly’s oral GLP-1 Foundayo demonstrated a 23% lower risk of major cardiovascular events (MACE-3 secondary endpoint) versus insulin glargine in the ACHIEVE-4 trial, per Dr. Daniel Skovronsky, Chief Scientific and Product Officer, on the Q1 earnings call. A similarly strong TRIUMPH-3 result for retatrutide would materially expand its payer coverage in the highest-priority patient segment.
The Business Behind the Pipeline
Before retatrutide becomes a revenue driver, the existing franchise has to keep performing. It is. CFO Lucas Montarce confirmed on the Q1 call that Mounjaro and Zepbound generated $12.8 billion in combined global revenue in Q1 2026, adding $6.7 billion of year-over-year growth. Lilly raised full-year 2026 guidance to $82–$85 billion, with the midpoint implying 28% revenue growth versus 2025.
Outside the U.S., Patrik Jonsson, President of Lilly International, confirmed Mounjaro held above 53% market share across more than 55 launched countries. In Brazil and Korea, shares sit at around 60%. When generic semaglutide entered India, Mounjaro prescriptions ran about 10% higher in the weeks that followed, suggesting tirzepatide’s dual-agonist profile holds a genuine clinical edge over semaglutide at scale.
Foundayo’s launch is early but sequenced. Ilya Yuffa, President of Lilly USA, confirmed on the Q1 call that more than 20,000 patients had started the drug by late April, with 80% being new to the GLP-1 class. Commercial access at two of three major pharmacy benefit managers (PBMs, companies that negotiate drug coverage for insurers) was confirmed for mid-May. Medicare Part D access through the GLP-1 Bridge program starts July 1, 2026, at a $50 monthly co-pay. Full direct-to-consumer TV advertising launches in Q3. Each of those is a dated access unlock.
On manufacturing, Lilly announced an additional $4.5 billion Indiana investment on May 6, bringing total Indiana capital expansion commitments since 2020 to more than $21 billion, as part of a broader U.S. manufacturing commitment exceeding $50 billion since 2020.
Is LLY Undervalued Today?
LLY currently trades at 22.58x NTM EV/EBITDA, compared to Merck at 10.01x and Novo Nordisk at 9.85x, per TIKR’s Competitors page. That premium is real, and it requires justification. The justification is growth: TIKR consensus estimates show a 2-year forward revenue CAGR of around 23%, against single-digit growth for most large-cap pharmaceutical peers.
The NTM P/E has already compressed from 35.55x in March 2025 to 28.63x today per TIKR, so the market has not been blind to execution risk. Bears are right that further multiple compression is the primary risk. If Foundayo’s prescription ramp disappoints in Q3 or TRIUMPH-3 comes in below expectations, the P/E contracts further even as the underlying business keeps growing, and near-term returns suffer.
On the Q1 call, CEO David Ricks addressed the pricing concern directly. Each time Lilly reduces GLP-1 pricing, volume expands in a way that is non-linear compared to traditional pharmaceuticals. The 10% rise in Mounjaro prescriptions after generic semaglutide entered India, and roughly 45% of total Zepbound Q1 prescriptions coming from self-pay patients, are evidence that price-sensitive demand is real and responsive. The market is 6% below LLY’s 52-week high of $1,133.95 and has not yet fully credited what TRIUMPH-1 just proved.
See how Eli Lilly performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $1,065.00
- TIKR Mid-Case Target: ~$2,029
- Potential Total Return: ~91%
- Annualized IRR: ~15% / year
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free!) >>>
The TIKR mid-case uses a revenue CAGR of around 12% and a net income margin of around 43% through the forecast period. The two primary revenue drivers are the continued global scaling of Mounjaro and Zepbound, which TIKR consensus estimates show growing from $65.2 billion in 2025 total revenue toward approximately $98 billion in 2027, and Foundayo’s commercial ramp through the back half of 2026. The margin driver is operating leverage: Lilly’s non-GAAP performance margin hit 50% in Q1 2026, up 7 percentage points year over year, while funding 42 active Phase 3 programs. Meanwhile, consensus estimates on TIKR show free cash flow growing from approximately $9.0 billion in 2025 to around $28.7 billion by 2027.
The primary risk is valuation multiple compression. The downside is not a broken business. It is a stock re-rating toward peer multiples while fundamentals stay strong, which can still mean flat or negative near-term returns. The upside is where retatrutide earns commercial approval, TRIUMPH-3 unlocks broad cardiovascular payer coverage, and Foundayo’s prescription ramp accelerates in Q3 and Q4, all of which would force meaningful upward revisions to long-term consensus estimates.
Conclusion
TRIUMPH-1 opened the regulatory chapter for retatrutide. The next data point that actually moves the investment thesis is TRIUMPH-3, the cardiovascular outcomes trial expected in the second half of 2026. The threshold that matters: cardiovascular event reduction is significant enough to earn broad payer coverage in the highest-volume obesity patient segment. A clean result would force consensus revenue models to be rebuilt upward. A disappointment would pressure the valuation premium Lilly currently carries over its large-cap pharmaceutical peers.
Watch TRIUMPH-3 in H2 2026. If the data delivers, $1,065 will look like a good entry point. If it disappoints, the current premium multiple becomes hard to defend.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Eli Lilly?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Eli Lilly, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Eli Lilly alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Eli Lilly on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
